# A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

> **NCT06660394** · PHASE3 · RECRUITING · sponsor: **Longboard Pharmaceuticals** · enrollment: 160 (estimated)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** LP352
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06660394
- **Lead sponsor:** Longboard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2026-08-21
- **Final completion:** 2026-10-02
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660394, "A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06660394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*